JAK/STAT blockade in cHL

ABSTRACT: Here we investigated the effects of JAK/STAT pharmacological inhibition on cHL cell models using ruxolitinib, a JAK 1/2 inhibitor. We use five classical Hodgkin lymphoma cell lines: L428, L1236, L540, KMH2, L591

ORGANISM(S): Homo sapiens

PROVIDER: GSE185818 | GEO | 2021/10/15

REPOSITORIES: GEO